[1]
|
Maraschin, J. de F. (2012) Classification of Diabetes. Advances in Experimental Medicine and Biology, 771, 12-19.
|
[2]
|
Wild, S., Roglic, G., Green, A., Sicree, R., et al. (2004) Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030. Diabetes Care, 27, 1047-1053. http://dx.doi.org/10.2337/diacare.27.5.1047
|
[3]
|
D’Souza, A., Hussain, M., Howarth, F.C., et al. (2009) Pathogenesis and Pathophysiology of Accelerated Atherosclerosis in the Diabetic Heart. Molecular and Cellular Biochemistry, 331, 89-116. http://dx.doi.org/10.1007/s11010-009-0148-8
|
[4]
|
Davies, M.J., Chubb, B.D., Smith, I.C., et al. (2012) Cost-Utility Analysis of Liraglutide Compared with Sulphonylurea or Sitagliptin, All as Add-On to Metformin Monotherapy in Type 2 Diabetes Mellitus. Diabetic Medicine, 29, 313-320. http://dx.doi.org/10.1111/j.1464-5491.2011.03429.x
|
[5]
|
Butler, A.E., Janson, J., Bonner-Weir, S., et al. (2003) Beta-Cell Deficit and Increased Beta-Cell Apoptosis in Humans with Type 2 Diabetes. Diabetes, 52, 102-110. http://dx.doi.org/10.2337/diabetes.52.1.102
|
[6]
|
Karaca, M., Magnan, C. and Kargar, C. (2009) Functional Pancreatic Beta-Cell Mass: Involvement in Type 2 Diabetes and Therapeutic Intervention. Diabetes & Metabolism, 35, 77-84. http://dx.doi.org/10.1016/j.diabet.2008.09.007
|
[7]
|
Creutzfeldt, W. and Ebert, R. (1985) New Developments in the Incretin Concept. Diabetologia, 28, 565-573. http://dx.doi.org/10.1007/BF00281990
|
[8]
|
Kim, M.H. and Lee, M.K. (2010) The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus. Korean Diabetes Journal, 34, 2-9. http://dx.doi.org/10.4093/kdj.2010.34.1.2
|
[9]
|
Baggio, L.L. and Drucker, D.J. (2007) Biology of Incretins: GLP-1 and GIP. Gastroenterology, 132, 2131-2157. http://dx.doi.org/10.1053/j.gastro.2007.03.054
|
[10]
|
Wideman, R.D. and Kieffer, T.J. (2004) Glucose-Dependent Insulinotropic Polypeptide as a Regulator of Beta Cell Function and Fate. Hormone and Metabolic Research, 36, 782-786. http://dx.doi.org/10.1055/s-2004-826164
|
[11]
|
Kieffer, T.J. and Habener, J.F. (1999) The Glucagon-Like Peptides. Endocrine Reviews, 20, 876-913. http://dx.doi.org/10.1210/edrv.20.6.0385
|
[12]
|
European Medicines Agency (2010) Novo Nordisk Summary of Product Characteristics: VictozaTM.
|
[13]
|
European Medicines Agency (2010) Eli Lilly & Co Summary of Product Characteristics: ByettaTM.
|
[14]
|
Aston-Mourney, K., Hull, R.L., Zraika, S., et al. (2011) Exendin-4 Increases Islet Amyloid Deposition but Offsets the Resultant Beta-Cell Toxicity in Human Islet Amyloid Polypeptide Transgenic Mouse Islets. Diabetologia, 54, 1756-1765. http://dx.doi.org/10.1007/s00125-011-2143-3
|
[15]
|
Fan, R., Kang, Z., He, L., et al. (2011) Exendin-4 Improves Blood Glucose Control in Both Young and Aging Normal Non-Diabetic Mice, Possible Contribution of Beta Cell Independent Effects. PLoS One, 6, e20443. http://dx.doi.org/10.1371/journal.pone.0020443
|
[16]
|
Degn, K.B., Juhl, C.B., Sturis, J., et al. (2004) One Week’s Treatment with the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and Alpha- and Beta-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes. Diabetes, 53, 1187-1194. http://dx.doi.org/10.2337/diabetes.53.5.1187
|
[17]
|
Iltz, J.L., Baker, D.E., Setter, S.M., et al. (2006) Exenatide: An Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus. Clinical Therapeutics, 28, 652-665. http://dx.doi.org/10.1016/j.clinthera.2006.05.006
|
[18]
|
Juhl, C.B., Hollingdal, M., Sturis, J., et al. (2002) Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes. Diabetes, 51, 424-429. http://dx.doi.org/10.2337/diabetes.51.2.424
|
[19]
|
Bregenholt, S., Møldrup, A., Blume, N., et al. (2005) The Long-Acting Glucagon-Like Peptide-1 Analogue, Liraglutide, Inhibits Beta-Cell Apoptosis in Vitro. Biochemical and Biophysical Research Communications, 330, 577-584. http://dx.doi.org/10.1016/j.bbrc.2005.03.013
|
[20]
|
Wajchenberg, B.L. (2007) Beta-Cell Failure in Diabetes and Preservation by Clinical Treatment. Endocrine Reviews, 28, 187-218. http://dx.doi.org/10.1210/10.1210/er.2006-0038
|
[21]
|
Lotfy, M., Singh, J., Kalász, H., et al. (2011) Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. The Open Medicinal Chemistry Journal, 5, 82-92. http://dx.doi.org/10.2174/1874104501105010082
|
[22]
|
Fakhoury, W.K., Lereun, C. and Wright, D. (2010) A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes. Pharmacology, 86, 44-57. http://dx.doi.org/10.1159/000314690
|
[23]
|
Brown, D.X. and Evans, M. (2012) Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. Journal of Nutrition and Metabolism, 2012, 381713. http://dx.doi.org/10.1155/2012/381713
|
[24]
|
Doggrell, S.A. (2013) Exenatide Extended-Release; Clinical Trials, Patient Preference, and Economic Considerations. Patient Preference and Adherence, 7, 35-45. http://dx.doi.org/10.2147/PPA.S30627
|
[25]
|
Karve, S., Cleves, M.A., Helm, M., et al. (2009) Prospective Validation of Eight Different Adherence Measures for Use with Administrative Claims Data among Patients with Schizophrenia. Value in Health, 12, 989-995. http://dx.doi.org/10.1111/j.1524-4733.2009.00543.x
|
[26]
|
Karve, S., Cleves, M.A., Helm, M., et al. (2008) An Empirical Basis for Standardizing Adherence Measures Derived from Administrative Claims Data among Diabetic Patients. Medical Care, 46, 1125-1133. http://dx.doi.org/10.1097/MLR.0b013e31817924d2
|
[27]
|
Colombo, G.L., Rossi, E., De Rosa, M., et al. (2012) Antidiabetic Therapy in Real Practice: Indicators for Adherence and Treatment Cost. Patient Preference and Adherence, 6, 653-661. http://dx.doi.org/10.2147/ppa.s33968
|
[28]
|
Dupclay, L., Eaddy, M., Jackson, J., et al. (2012) Real-World Impact of Reminder Packaging on Antihypertensive Treatment Adherence and Persistence. Patient Preference and Adherence, 6, 499-507.
|
[29]
|
Egede, L.E., Gebregziabher, M., Dismuke, C.E., et al. (2012) Medication Nonadherence in Diabetes: Longitudinal Effects on Costs and Potential Cost Savings from Improvement. Diabetes Care, 35, 2533-2539. http://dx.doi.org/10.2337/dc12-0572
|
[30]
|
Vollmer, W.M., Feldstein, A., Smith, D.H., et al. (2011) Use of Health Information Technology to Improve Medication Adherence. American Journal of Managed Care, 17, SP79-S87.
|
[31]
|
Ratanawongsa, N., Karter, A.J., Parker, M.M., et al. (2013) Communication and Medication Refill Adherence: The Diabetes Study of Northern California. JAMA Internal Medicine, 173, 210-218. http://dx.doi.org/10.1001/jamainternmed.2013.1216
|
[32]
|
Kocarnik, B.M., Liu, C.F., Wong, E.S., et al. (2012) Does the Presence of a Pharmacist in Primary Care Clinics Improve Diabetes Medication Adherence? BMC Health Services Research, 12, 391. http://dx.doi.org/10.1186/1472-6963-12-391
|
[33]
|
Cocohoba, J.M., Murphy, P., Pietrandoni, G., et al. (2003) Improved Antiretroviral Refill Adherence in HIV-Focused Community Pharmacies. Journal of American Pharmacists Association, 52, e67-e73.
|
[34]
|
Sharma, K.P. and Taylor, T.N. (2012) Pharmacy Effect on Adherence to Antidiabetic Medications. Medical Care, 50, 685-691. http://dx.doi.org/10.1097/MLR.0b013e318249d800
|
[35]
|
Yeaw, J., Benner, J.S., Walt, J.G., et al. (2009) Comparing Adherence and Persistence across 6 Chronic Medication Classes. Journal of Managed Care Pharmacy, 15, 728-740.
|
[36]
|
van den Boogaard, J., Lyimo, R.A., Boeree, M.J., et al. (2011) Electronic Monitoring of Treatment Adherence and Validation of Alternative Adherence Measures in Tuberculosis Patients: A Pilot Study. Bulletin of the World Health Organization, 89, 632-639. http://dx.doi.org/10.2471/BLT.11.086462
|
[37]
|
Gu, Q., Zeng, F., Patel, B.V., et al. (2010) Part D Coverage Gap and Adherence to Diabetes Medications. American Journal of Managed Care, 16, 911-918.
|
[38]
|
Egede, L.E., Gebregziabher, M., Hunt, K.J., et al. (2011) Regional, Geographic, and Ethnic Differences in Medication Adherence among Adults with Type 2 Diabetes. The Annals of Pharmacotherapy, 45, 169-178. http://dx.doi.org/10.1345/aph.1P442
|
[39]
|
Friedman, D.S., Quigley, H.A., Gelb, L., et al. (2007) Using Pharmacy Claims Data to Study Adherence to Glaucoma Medications: Methodology and Findings of the Glaucoma Adherence and Persistency Study (GAPS). Investigative Ophthalmology & Visual Science, 48, 5052-5057. http://dx.doi.org/10.1167/iovs.07-0290
|
[40]
|
Hess, L.M., Raebel, M.A., Conner, D.A., et al. (2006) Measurement of Adherence in Pharmacy Administrative Databases: A Proposal for Standard Definitions and Preferred Measures. Annals of Pharmacotherapy, 40, 1280-1288. http://dx.doi.org/10.1345/aph.1H018
|
[41]
|
Santoleri, F., Sorice, P., Lasala, R., et al. (2013) Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice. PLoS One, 8, e56813. http://dx.doi.org/10.1371/journal.pone.0056813
|
[42]
|
Sattler, E.L., Lee, J.S. and Perri 3rd, M. (2013) Medication (Re)fill Adherence Measures Derived from Pharmacy Claims Data in Older Americans: A Review of the Literature. Drugs & Aging, 30, 383-399. http://dx.doi.org/10.1007/s40266-013-0074-z
|
[43]
|
Peterson, A.M., Nau, D.P., Cramer, J.A., et al. (2007) A Checklist for Medication Compliance and Persistence Studies Using Retrospective Database. Value in Health, 10, 3-12.
|
[44]
|
WHO (2013) Guidelines for ATC Classification and DDD Assignment 2012. Collaborating Centre for Drug Statistics Methodology, Oslo.
|